Homology Medicines Inc. (NASDAQ:FIXX) went down by -10.00% from its latest closing price compared to the recent 1-year high of $5.34. The company’s stock price has collected -20.59% of loss in the last five trading sessions.
Is It Worth Investing in Homology Medicines Inc. (NASDAQ :FIXX) Right Now?
Plus, the 36-month beta value for FIXX is at -0.18. Opinions of the stock are interesting as 4 analysts out of 9 who provided ratings for Homology Medicines Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 4 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $7.59, which is $6.52 above the current price. FIXX currently public float of 52.23M and currently shorts hold a 2.15% ratio of that float. Today, the average trading volume of FIXX was 199.66K shares.
FIXX’s Market Performance
FIXX stocks went down by -20.59% for the week, with a monthly jump of 8.00% and a quarterly performance of -46.18%, while its annual performance rate touched -68.85%. The volatility ratio for the week stands at 13.60% while the volatility levels for the past 30 days are set at 9.97% for Homology Medicines Inc. The simple moving average for the period of the last 20 days is 2.11% for FIXX stocks with a simple moving average of -26.84% for the last 200 days.
Analysts’ Opinion of FIXX
Many brokerage firms have already submitted their reports for FIXX stocks, with BTIG Research repeating the rating for FIXX by listing it as a “Neutral.” The predicted price for FIXX in the upcoming period, according to BTIG Research is $29 based on the research report published on February 22nd of the current year 2022.
FIXX Trading at 3.15% from the 50-Day Moving Average
After a stumble in the market that brought FIXX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.66% of loss for the given period.
Volatility was left at 9.97%, however, over the last 30 days, the volatility rate increased by 13.60%, as shares surge +9.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.06% lower at present.
During the last 5 trading sessions, FIXX fell by -20.59%, which changed the moving average for the period of 200-days by -58.78% in comparison to the 20-day moving average, which settled at $1.5935. In addition, Homology Medicines Inc. saw -55.49% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at FIXX starting from Cohn Gabriel, who sale 1,661 shares at the price of $3.78 back on Jan 05. After this action, Cohn Gabriel now owns 2,629 shares of Homology Medicines Inc., valued at $6,279 using the latest closing price.
Seymour Albert, the Chief Scientific Officer of Homology Medicines Inc., sale 1,661 shares at $3.78 during a trade that took place back on Jan 05, which means that Seymour Albert is holding 131,646 shares at $6,279 based on the most recent closing price.
Stock Fundamentals for FIXX
Current profitability levels for the company are sitting at:
- -282.44 for the present operating margin
- +71.91 for the gross margin
The net margin for Homology Medicines Inc. stands at -281.90. Equity return is now at value -1.90, with -1.60 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 11.14.